United Therapeutics (NASDAQ:UTHR) PT Raised to $400.00 at Oppenheimer

United Therapeutics (NASDAQ:UTHR) had its price target upped by investment analysts at Oppenheimer from $375.00 to $400.00 in a report released on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s target price points to a potential upside of 52.44% from the stock’s previous close.

Several other research analysts also recently weighed in on UTHR. Wedbush reissued an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. SVB Leerink began coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a report on Thursday. Finally, The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $213.00 to $215.00 in a report on Monday, February 12th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $308.78.

United Therapeutics Stock Performance

NASDAQ:UTHR traded up $4.27 during midday trading on Thursday, reaching $262.40. The stock had a trading volume of 779,523 shares, compared to its average volume of 541,180. The company has a quick ratio of 4.28, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics has a 12-month low of $204.44 and a 12-month high of $262.51. The stock has a market cap of $11.64 billion, a P/E ratio of 12.41 and a beta of 0.54. The firm has a fifty day simple moving average of $236.86 and a two-hundred day simple moving average of $229.40.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. During the same quarter in the previous year, the firm earned $4.86 earnings per share. The firm’s revenue was up 33.7% on a year-over-year basis. On average, equities analysts expect that United Therapeutics will post 23.75 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $215.31, for a total value of $1,291,860.00. Following the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at approximately $7,880,130.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total transaction of $929,124.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $33,551.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at $7,880,130.69. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 141,790 shares of company stock valued at $33,572,685. Company insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently modified their holdings of UTHR. Asset Management One Co. Ltd. boosted its holdings in United Therapeutics by 2.8% in the 3rd quarter. Asset Management One Co. Ltd. now owns 22,968 shares of the biotechnology company’s stock worth $5,188,000 after acquiring an additional 633 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in United Therapeutics by 9.0% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 1,705 shares of the biotechnology company’s stock worth $385,000 after buying an additional 141 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its position in United Therapeutics by 125.2% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 87,048 shares of the biotechnology company’s stock valued at $19,662,000 after buying an additional 48,397 shares during the last quarter. Raymond James & Associates grew its stake in shares of United Therapeutics by 1.7% during the third quarter. Raymond James & Associates now owns 28,054 shares of the biotechnology company’s stock valued at $6,337,000 after acquiring an additional 471 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its position in shares of United Therapeutics by 48.8% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 2,345 shares of the biotechnology company’s stock worth $530,000 after acquiring an additional 769 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.